The GVHD market is advancing through rising transplant rates and treatment innovation. Leading companies like Incyte, Pfizer, and Equillium are developing novel JAK inhibitors and biologics that improve response rates and reduce corticosteroid use. Enhanced diagnostic tools and treatment guidelines are supporting more effective management of this transplant complication.
Explore Market Report:
https://www.delveinsight.com/i....nfographics/graft-ve
Comment
Share
